Pular para o conteúdo
Merck
Todas as fotos(2)

Documentos

GF58573648

Lutetium

powder, 1g, max. particle size 500 micron, 99.9%

Sinônimo(s):

Lutetium, LU006010

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
Lu
Número CAS:
Peso molecular:
174.97
Número MDL:
Código UNSPSC:
11101711
ID de substância PubChem:
NACRES:
NA.23

Ensaio

99.9%

forma

powder

fabricante/nome comercial

Goodfellow 585-736-48

resistividade

54 μΩ-cm, 20°C

tamanho de partícula

500 μm

pb

3402 °C (lit.)

pf

1663 °C (lit.)

densidade

9.84 g/mL at 25 °C (lit.)

cadeia de caracteres SMILES

[Lu]

InChI

1S/Lu

chave InChI

OHSVLFRHMCKCQY-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

For updated SDS information please visit www.goodfellow.com.

Informações legais

Product of Goodfellow

Pictogramas

Flame

Palavra indicadora

Danger

Frases de perigo

Declarações de precaução

Classificações de perigo

Flam. Sol. 1

Código de classe de armazenamento

4.1B - Flammable solid hazardous materials

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

R O Perez et al.
Techniques in coloproctology, 18(8), 699-708 (2014-02-11)
Molecular imaging using positron emission tomography/computerized tomography (PET/CT) may add relevant incremental diagnostic information to standard structural cross-sectional imaging. Such information may allow identification of patients with rectal cancer that are more likely to develop complete tumor regression after neoadjuvant
S Panigone et al.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 50(4), 310-321 (2006-10-18)
Optimization of therapy for individual patients remains a goal of clinical practice. Radionuclide imaging can identify those patients who may benefit from subsequent targeted therapy by providing regional information on the distribution of the target. An ideal situation may be
B L R Kam et al.
European journal of nuclear medicine and molecular imaging, 39 Suppl 1, S103-S112 (2012-03-06)
Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with (177)Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT). The
Alin Chirindel et al.
AJR. American journal of roentgenology, 204(5), 1093-1099 (2015-04-24)
The purpose of this study is to evaluate the performance of PET-derived parameters as prognostic markers for overall survival (OS) and progression-free survival (PFS) outcome in patients with pancreatic adenocarcinoma. We conducted a retrospective study of 106 patients (62 men
Vijay Kumar Ichpujani et al.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 72(11), 2319-2332 (2014-12-02)
The fusion imaging modality of positron-emission tomography-computed tomography (PET-CT) has emerged as an important modality in the management of recurrent head and neck tumors. The aims of this study were to assess the role of PET-CT in the detection of

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica